{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-033402","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.013543+00:00","generated_at":"2026-06-10T06:13:44.155697+00:00","sec_items":["2.01","7.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Baxter completes sale of BioPharma Solutions business for $4.25B in cash","bullets":["Closed sale of Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH to Bamboo BidCo entities for $4.25B.","Net pre-tax cash proceeds of approximately $3.96B received at closing.","Company plans to use ~$3.4B of net after-tax proceeds to pay down debt through H1 2024.","Prior full-year 2023 guidance scenario assuming no transaction is now withdrawn; only scenario with close remains."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-033402","json":"https://secwatch.observer/filing/0001628280-23-033402.json","markdown":"https://secwatch.observer/filing/0001628280-23-033402.md","text":"https://secwatch.observer/filing/0001628280-23-033402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000162828023033402/0001628280-23-033402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000162828023033402/bax-20230929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:13:44.155697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}